# Tirzepatide SURPASS-6: HbA1c and weight vs insulin lispro

Source: https://pepvault.app/research/tirzepatide-surpass-6-2023

Last updated: 2026-11-17

Use: © PepVault. Read and cite with a link. Copying, bulk scraping, rewriting or republishing is not permitted (https://pepvault.app/terms#content).

[Research](https://pepvault.app/research) [Tirzepatide](https://pepvault.app/research#tirzepatide)

Randomized trial · people

# Tirzepatide: HbA1c fell 2.1% vs 1.1% with insulin lispro in SURPASS-6

Checked against the paper November 2026 Randomized trial [Published by PepVault](https://pepvault.app/guides/how-we-research)

## The takeaway

For people with type 2 diabetes already on basal insulin, this trial found adding tirzepatide lowered HbA1c and weight more than mealtime insulin, with fewer low blood sugar events, while gut symptoms were its most common side effect.

- **Kind:** Randomized trial
- **Studied in:** People
- **Number studied:** 1428
- **Published:** 2023
- **Journal:** JAMA

## What they tested

The team tested whether weekly tirzepatide works at least as well as mealtime insulin lispro when added to insulin glargine in people with type 2 diabetes whose blood sugar was not controlled on basal insulin.

## How the study was done

An open-label, randomized phase 3b trial of 1428 adults with type 2 diabetes who were already using basal insulin, run at 135 sites across 15 countries. On top of insulin glargine, each person got weekly tirzepatide shots (5 mg, 10 mg or 15 mg arms) or insulin lispro 3 times a day for 52 weeks.

<!--promo-->

Model. Individual results vary.

PepVault for iPhone

## Taking tirzepatide? Keep your own record

Log each dose, your weight and how you feel, in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=study-card-flow&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## What they found

At week 52, HbA1c (a 3-month average of blood sugar) changed by -2.1% with tirzepatide (all doses pooled) and -1.1% with insulin lispro, reaching 6.7% vs 7.7%, an estimated difference of -0.98%; tirzepatide was both noninferior and superior. Body weight changed by -9.0 kg with tirzepatide and 3.2 kg with insulin lispro. An HbA1c under 7.0% was reached by 68% on tirzepatide and 36% on insulin lispro. Low blood sugar events (under 54 mg/dL or severe) ran at 0.4 per patient-year with tirzepatide and 4.4 with insulin lispro, while the most common tirzepatide side effects were mild to moderate gut symptoms such as nausea in 14%-26%.

## What it doesn’t show

The trial was open-label, so participants and staff knew which treatment was given. It lasted 52 weeks and only included adults already on basal insulin, compared against mealtime insulin rather than placebo.

## The paper

Rosenstock et al. Tirzepatide vs Insulin Lispro Added to Basal Insulin in Type 2 Diabetes: The SURPASS-6 Randomized Clinical Trial. JAMA. 2023.

- [PubMed (PMID 37786396)](https://pubmed.ncbi.nlm.nih.gov/37786396/)
- [The paper (DOI 10.1001/jama.2023.20294)](https://doi.org/10.1001/jama.2023.20294)
- [ClinicalTrials.gov (NCT04537923)](https://clinicaltrials.gov/study/NCT04537923)

## The compound

- [Tirzepatide: how it works, half-life, studied range and evidence](https://pepvault.app/peptides/tirzepatide)
- [Tirzepatide dose guide](https://pepvault.app/lab/dosage/tirzepatide)

## With this study

### Tirzepatide

- [Tirzepatide: the full reference](https://pepvault.app/peptides/tirzepatide)
- [Tirzepatide dose guide](https://pepvault.app/lab/dosage/tirzepatide)

### Mixing charts

- [5 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-5mg)
- [10 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-10mg)
- [15 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-15mg)
- [30 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-30mg)
- [60 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-60mg)

### Studies

- [Tirzepatide plus apitegromab: 1.9 kg less lean mass loss in EMBRAZE](https://pepvault.app/research/tirzepatide-embraze-2026)
- [Dulaglutide: switching to tirzepatide beat dose escalation on HbA1c](https://pepvault.app/research/dulaglutide-surpass-switch-2025)
- [Tirzepatide: up to 19.7% weight loss at 176 weeks in SURMOUNT-1](https://pepvault.app/research/tirzepatide-surmount-1-2025-39536238)
- [All 15 studies](https://pepvault.app/research#tirzepatide)

### Compared with

- [Retatrutide vs Tirzepatide](https://pepvault.app/peptides/compare/retatrutide-vs-tirzepatide)
- [Semaglutide vs Tirzepatide](https://pepvault.app/peptides/compare/semaglutide-vs-tirzepatide)
- [Mazdutide vs Tirzepatide](https://pepvault.app/peptides/compare/mazdutide-vs-tirzepatide)
- [Tirzepatide vs Liraglutide](https://pepvault.app/peptides/compare/tirzepatide-vs-liraglutide)
- [Tirzepatide vs Dulaglutide](https://pepvault.app/peptides/compare/tirzepatide-vs-dulaglutide)
- [Orforglipron vs Tirzepatide](https://pepvault.app/peptides/compare/orforglipron-vs-tirzepatide)

### Tools

- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [How long will my vial last?](https://pepvault.app/tools/how-long-will-my-vial-last)
- [Is my mixed vial still good?](https://pepvault.app/tools/reconstituted-peptide-expiry)
- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)
- [GLP-1 titration planner](https://pepvault.app/tools/glp1-titration-calculator)
- [GLP-1 weight loss by week](https://pepvault.app/tools/glp1-weight-loss-by-week)

### Terms on this page

- [Placebo](https://pepvault.app/glossary/placebo)

## More studies on Tirzepatide

- [Tirzepatide plus apitegromab: 1.9 kg less lean mass loss in EMBRAZE](https://pepvault.app/research/tirzepatide-embraze-2026) Randomized trial · people · 2026
- [Dulaglutide: switching to tirzepatide beat dose escalation on HbA1c](https://pepvault.app/research/dulaglutide-surpass-switch-2025) Randomized trial · people · 2025
- [Tirzepatide: up to 19.7% weight loss at 176 weeks in SURMOUNT-1](https://pepvault.app/research/tirzepatide-surmount-1-2025-39536238) Randomized trial · people · 2025
- [Tirzepatide: about 75% of weight lost was fat in SURMOUNT-1](https://pepvault.app/research/tirzepatide-surmount-1-2025-39996356) Randomized trial · people · 2025
- [Tirzepatide: most reached a weight plateau by week 72 in SURMOUNT-1](https://pepvault.app/research/tirzepatide-surmount-1-and-surmount-4-2025) Randomized trial · people · 2025
- [Tirzepatide: 20.2% weight loss vs 13.7% on semaglutide at 72 weeks](https://pepvault.app/research/tirzepatide-surmount-5-2025) Randomized trial · people · 2025
- [Every study on Tirzepatide](https://pepvault.app/research#tirzepatide)

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed November 2026. Spot an error? [feedback@pepvault.app](mailto:feedback@pepvault.app). [How we research](https://pepvault.app/guides/how-we-research). This page reports one study; it is not medical advice.

<!--promo-->

[Track it in the app](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=study-card-next&mt=8)

<!--/promo-->

<!--promo-->

PepVault for iPhone

## Taking tirzepatide? Keep your own record

Log each dose, your weight and how you feel, in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=study-card-end&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

<!--promo-->

Model. Individual results vary.

PepVault for iPhone

## Taking tirzepatide? Keep your own record

Log each dose, your weight and how you feel, in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=study-card-rail&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## With this study

### Tirzepatide

- [Tirzepatide: the full reference](https://pepvault.app/peptides/tirzepatide)
- [Tirzepatide dose guide](https://pepvault.app/lab/dosage/tirzepatide)

### Mixing charts

- [5 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-5mg)
- [10 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-10mg)
- [15 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-15mg)
- [30 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-30mg)
- [60 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-60mg)

### Studies

- [Tirzepatide plus apitegromab: 1.9 kg less lean mass loss in EMBRAZE](https://pepvault.app/research/tirzepatide-embraze-2026)
- [Dulaglutide: switching to tirzepatide beat dose escalation on HbA1c](https://pepvault.app/research/dulaglutide-surpass-switch-2025)
- [Tirzepatide: up to 19.7% weight loss at 176 weeks in SURMOUNT-1](https://pepvault.app/research/tirzepatide-surmount-1-2025-39536238)
- [All 15 studies](https://pepvault.app/research#tirzepatide)

### Compared with

- [Retatrutide vs Tirzepatide](https://pepvault.app/peptides/compare/retatrutide-vs-tirzepatide)
- [Semaglutide vs Tirzepatide](https://pepvault.app/peptides/compare/semaglutide-vs-tirzepatide)
- [Mazdutide vs Tirzepatide](https://pepvault.app/peptides/compare/mazdutide-vs-tirzepatide)
- [Tirzepatide vs Liraglutide](https://pepvault.app/peptides/compare/tirzepatide-vs-liraglutide)
- [Tirzepatide vs Dulaglutide](https://pepvault.app/peptides/compare/tirzepatide-vs-dulaglutide)
- [Orforglipron vs Tirzepatide](https://pepvault.app/peptides/compare/orforglipron-vs-tirzepatide)

### Tools

- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [How long will my vial last?](https://pepvault.app/tools/how-long-will-my-vial-last)
- [Is my mixed vial still good?](https://pepvault.app/tools/reconstituted-peptide-expiry)
- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)
- [GLP-1 titration planner](https://pepvault.app/tools/glp1-titration-calculator)
- [GLP-1 weight loss by week](https://pepvault.app/tools/glp1-weight-loss-by-week)

### Terms on this page

- [Placebo](https://pepvault.app/glossary/placebo)

<!--promo-->

PepVault for iPhone

## Taking tirzepatide? Keep your own record

Log each dose, your weight and how you feel, in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=study-card-sticky&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

## Research

- [All studies](https://pepvault.app/research)
- [Every study on Tirzepatide](https://pepvault.app/research#tirzepatide)

## The library

- [Tirzepatide](https://pepvault.app/peptides/tirzepatide)
- [Tirzepatide dose guide](https://pepvault.app/lab/dosage/tirzepatide)
- [The peptide reference library](https://pepvault.app/peptides)

## How we work

- [How we research](https://pepvault.app/guides/how-we-research)
- [How we check the library](https://pepvault.app/about#library)

PepVault is a research and tracking resource, not medical advice. Ranges are what studies used, never a dose for you. Brand names are trademarks of their owners; PepVault is independent of them.

PepVault is a private research and tracking tool, not medical advice. The information here is reference material from published literature and community use — always verify it and discuss any protocol with a qualified clinician before changing it. Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound, Saxenda, Victoza and Trulicity are trademarks of their respective owners; PepVault is independent and not affiliated with or endorsed by any manufacturer.

© 2026 PepVault. Our text, data and tools may not be copied, scraped or republished without [permission](https://pepvault.app/terms#content).
